
Global NK-1 Receptor Antagonists Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global NK-1 Receptor Antagonists market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of NK-1 Receptor Antagonists include Dr. Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, Glenmark, Helsinn Healthcare, Heron Therapeutics, Lupin, MSN and Mylan, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for NK-1 Receptor Antagonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of NK-1 Receptor Antagonists, also provides the sales of main regions and countries. Of the upcoming market potential for NK-1 Receptor Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the NK-1 Receptor Antagonists sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global NK-1 Receptor Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for NK-1 Receptor Antagonists sales, projected growth trends, production technology, application and end-user industry.
NK-1 Receptor Antagonists Segment by Company
Dr. Reddy's Laboratories
Eugia Pharma
Fresenius Kabi
Glenmark
Helsinn Healthcare
Heron Therapeutics
Lupin
MSN
Mylan
Steriscience
TerSera Therapeutics
Teva
Torrent Pharmaceuticals
Beijing Sihuan Pharmaceutical
Hansoh Pharma
Merck
Qilu Pharmaceutical
Sandoz
Yichang Humanwell Pharmaceutical
Chia Tai Tianqing Pharmaceutical
NK-1 Receptor Antagonists Segment by Type
Netupitant
Maropitant
Rolapitant
Fosaprepitant
Aprepitant
Other
NK-1 Receptor Antagonists Segment by Application
Chemotherapy-induced Nausea and Vomiting (CINV)
Postoperative Nausea and Vomiting (PONV)
Other
NK-1 Receptor Antagonists Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK-1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NK-1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK-1 Receptor Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of NK-1 Receptor Antagonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NK-1 Receptor Antagonists sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global NK-1 Receptor Antagonists market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of NK-1 Receptor Antagonists include Dr. Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, Glenmark, Helsinn Healthcare, Heron Therapeutics, Lupin, MSN and Mylan, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for NK-1 Receptor Antagonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of NK-1 Receptor Antagonists, also provides the sales of main regions and countries. Of the upcoming market potential for NK-1 Receptor Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the NK-1 Receptor Antagonists sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global NK-1 Receptor Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for NK-1 Receptor Antagonists sales, projected growth trends, production technology, application and end-user industry.
NK-1 Receptor Antagonists Segment by Company
Dr. Reddy's Laboratories
Eugia Pharma
Fresenius Kabi
Glenmark
Helsinn Healthcare
Heron Therapeutics
Lupin
MSN
Mylan
Steriscience
TerSera Therapeutics
Teva
Torrent Pharmaceuticals
Beijing Sihuan Pharmaceutical
Hansoh Pharma
Merck
Qilu Pharmaceutical
Sandoz
Yichang Humanwell Pharmaceutical
Chia Tai Tianqing Pharmaceutical
NK-1 Receptor Antagonists Segment by Type
Netupitant
Maropitant
Rolapitant
Fosaprepitant
Aprepitant
Other
NK-1 Receptor Antagonists Segment by Application
Chemotherapy-induced Nausea and Vomiting (CINV)
Postoperative Nausea and Vomiting (PONV)
Other
NK-1 Receptor Antagonists Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK-1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NK-1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK-1 Receptor Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of NK-1 Receptor Antagonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NK-1 Receptor Antagonists sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
207 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 NK-1 Receptor Antagonists Market by Type
- 1.2.1 Global NK-1 Receptor Antagonists Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Netupitant
- 1.2.3 Maropitant
- 1.2.4 Rolapitant
- 1.2.5 Fosaprepitant
- 1.2.6 Aprepitant
- 1.2.7 Other
- 1.3 NK-1 Receptor Antagonists Market by Application
- 1.3.1 Global NK-1 Receptor Antagonists Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Chemotherapy-induced Nausea and Vomiting (CINV)
- 1.3.3 Postoperative Nausea and Vomiting (PONV)
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 NK-1 Receptor Antagonists Market Dynamics
- 2.1 NK-1 Receptor Antagonists Industry Trends
- 2.2 NK-1 Receptor Antagonists Industry Drivers
- 2.3 NK-1 Receptor Antagonists Industry Opportunities and Challenges
- 2.4 NK-1 Receptor Antagonists Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global NK-1 Receptor Antagonists Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global NK-1 Receptor Antagonists Revenue by Region
- 3.2.1 Global NK-1 Receptor Antagonists Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global NK-1 Receptor Antagonists Revenue by Region (2020-2025)
- 3.2.3 Global NK-1 Receptor Antagonists Revenue by Region (2026-2031)
- 3.2.4 Global NK-1 Receptor Antagonists Revenue Market Share by Region (2020-2031)
- 3.3 Global NK-1 Receptor Antagonists Sales Estimates and Forecasts 2020-2031
- 3.4 Global NK-1 Receptor Antagonists Sales by Region
- 3.4.1 Global NK-1 Receptor Antagonists Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global NK-1 Receptor Antagonists Sales by Region (2020-2025)
- 3.4.3 Global NK-1 Receptor Antagonists Sales by Region (2026-2031)
- 3.4.4 Global NK-1 Receptor Antagonists Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global NK-1 Receptor Antagonists Revenue by Manufacturers
- 4.1.1 Global NK-1 Receptor Antagonists Revenue by Manufacturers (2020-2025)
- 4.1.2 Global NK-1 Receptor Antagonists Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global NK-1 Receptor Antagonists Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global NK-1 Receptor Antagonists Sales by Manufacturers
- 4.2.1 Global NK-1 Receptor Antagonists Sales by Manufacturers (2020-2025)
- 4.2.2 Global NK-1 Receptor Antagonists Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global NK-1 Receptor Antagonists Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global NK-1 Receptor Antagonists Sales Price by Manufacturers (2020-2025)
- 4.4 Global NK-1 Receptor Antagonists Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global NK-1 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global NK-1 Receptor Antagonists Manufacturers, Product Type & Application
- 4.7 Global NK-1 Receptor Antagonists Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global NK-1 Receptor Antagonists Market CR5 and HHI
- 4.8.2 2024 NK-1 Receptor Antagonists Tier 1, Tier 2, and Tier 3
- 5 NK-1 Receptor Antagonists Market by Type
- 5.1 Global NK-1 Receptor Antagonists Revenue by Type
- 5.1.1 Global NK-1 Receptor Antagonists Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global NK-1 Receptor Antagonists Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global NK-1 Receptor Antagonists Revenue Market Share by Type (2020-2031)
- 5.2 Global NK-1 Receptor Antagonists Sales by Type
- 5.2.1 Global NK-1 Receptor Antagonists Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global NK-1 Receptor Antagonists Sales by Type (2020-2031) & (K Units)
- 5.2.3 Global NK-1 Receptor Antagonists Sales Market Share by Type (2020-2031)
- 5.3 Global NK-1 Receptor Antagonists Price by Type
- 6 NK-1 Receptor Antagonists Market by Application
- 6.1 Global NK-1 Receptor Antagonists Revenue by Application
- 6.1.1 Global NK-1 Receptor Antagonists Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global NK-1 Receptor Antagonists Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global NK-1 Receptor Antagonists Revenue Market Share by Application (2020-2031)
- 6.2 Global NK-1 Receptor Antagonists Sales by Application
- 6.2.1 Global NK-1 Receptor Antagonists Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global NK-1 Receptor Antagonists Sales by Application (2020-2031) & (K Units)
- 6.2.3 Global NK-1 Receptor Antagonists Sales Market Share by Application (2020-2031)
- 6.3 Global NK-1 Receptor Antagonists Price by Application
- 7 Company Profiles
- 7.1 Dr. Reddy's Laboratories
- 7.1.1 Dr. Reddy's Laboratories Comapny Information
- 7.1.2 Dr. Reddy's Laboratories Business Overview
- 7.1.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
- 7.1.5 Dr. Reddy's Laboratories Recent Developments
- 7.2 Eugia Pharma
- 7.2.1 Eugia Pharma Comapny Information
- 7.2.2 Eugia Pharma Business Overview
- 7.2.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
- 7.2.5 Eugia Pharma Recent Developments
- 7.3 Fresenius Kabi
- 7.3.1 Fresenius Kabi Comapny Information
- 7.3.2 Fresenius Kabi Business Overview
- 7.3.3 Fresenius Kabi NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio
- 7.3.5 Fresenius Kabi Recent Developments
- 7.4 Glenmark
- 7.4.1 Glenmark Comapny Information
- 7.4.2 Glenmark Business Overview
- 7.4.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
- 7.4.5 Glenmark Recent Developments
- 7.5 Helsinn Healthcare
- 7.5.1 Helsinn Healthcare Comapny Information
- 7.5.2 Helsinn Healthcare Business Overview
- 7.5.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
- 7.5.5 Helsinn Healthcare Recent Developments
- 7.6 Heron Therapeutics
- 7.6.1 Heron Therapeutics Comapny Information
- 7.6.2 Heron Therapeutics Business Overview
- 7.6.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
- 7.6.5 Heron Therapeutics Recent Developments
- 7.7 Lupin
- 7.7.1 Lupin Comapny Information
- 7.7.2 Lupin Business Overview
- 7.7.3 Lupin NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Lupin NK-1 Receptor Antagonists Product Portfolio
- 7.7.5 Lupin Recent Developments
- 7.8 MSN
- 7.8.1 MSN Comapny Information
- 7.8.2 MSN Business Overview
- 7.8.3 MSN NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 MSN NK-1 Receptor Antagonists Product Portfolio
- 7.8.5 MSN Recent Developments
- 7.9 Mylan
- 7.9.1 Mylan Comapny Information
- 7.9.2 Mylan Business Overview
- 7.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
- 7.9.5 Mylan Recent Developments
- 7.10 Steriscience
- 7.10.1 Steriscience Comapny Information
- 7.10.2 Steriscience Business Overview
- 7.10.3 Steriscience NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
- 7.10.5 Steriscience Recent Developments
- 7.11 TerSera Therapeutics
- 7.11.1 TerSera Therapeutics Comapny Information
- 7.11.2 TerSera Therapeutics Business Overview
- 7.11.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
- 7.11.5 TerSera Therapeutics Recent Developments
- 7.12 Teva
- 7.12.1 Teva Comapny Information
- 7.12.2 Teva Business Overview
- 7.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
- 7.12.5 Teva Recent Developments
- 7.13 Torrent Pharmaceuticals
- 7.13.1 Torrent Pharmaceuticals Comapny Information
- 7.13.2 Torrent Pharmaceuticals Business Overview
- 7.13.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
- 7.13.5 Torrent Pharmaceuticals Recent Developments
- 7.14 Beijing Sihuan Pharmaceutical
- 7.14.1 Beijing Sihuan Pharmaceutical Comapny Information
- 7.14.2 Beijing Sihuan Pharmaceutical Business Overview
- 7.14.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.14.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
- 7.14.5 Beijing Sihuan Pharmaceutical Recent Developments
- 7.15 Hansoh Pharma
- 7.15.1 Hansoh Pharma Comapny Information
- 7.15.2 Hansoh Pharma Business Overview
- 7.15.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.15.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
- 7.15.5 Hansoh Pharma Recent Developments
- 7.16 Merck
- 7.16.1 Merck Comapny Information
- 7.16.2 Merck Business Overview
- 7.16.3 Merck NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.16.4 Merck NK-1 Receptor Antagonists Product Portfolio
- 7.16.5 Merck Recent Developments
- 7.17 Qilu Pharmaceutical
- 7.17.1 Qilu Pharmaceutical Comapny Information
- 7.17.2 Qilu Pharmaceutical Business Overview
- 7.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
- 7.17.5 Qilu Pharmaceutical Recent Developments
- 7.18 Sandoz
- 7.18.1 Sandoz Comapny Information
- 7.18.2 Sandoz Business Overview
- 7.18.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.18.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
- 7.18.5 Sandoz Recent Developments
- 7.19 Yichang Humanwell Pharmaceutical
- 7.19.1 Yichang Humanwell Pharmaceutical Comapny Information
- 7.19.2 Yichang Humanwell Pharmaceutical Business Overview
- 7.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
- 7.19.5 Yichang Humanwell Pharmaceutical Recent Developments
- 7.20 Chia Tai Tianqing Pharmaceutical
- 7.20.1 Chia Tai Tianqing Pharmaceutical Comapny Information
- 7.20.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 7.20.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.20.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
- 7.20.5 Chia Tai Tianqing Pharmaceutical Recent Developments
- 8 North America
- 8.1 North America NK-1 Receptor Antagonists Market Size by Type
- 8.1.1 North America NK-1 Receptor Antagonists Revenue by Type (2020-2031)
- 8.1.2 North America NK-1 Receptor Antagonists Sales by Type (2020-2031)
- 8.1.3 North America NK-1 Receptor Antagonists Price by Type (2020-2031)
- 8.2 North America NK-1 Receptor Antagonists Market Size by Application
- 8.2.1 North America NK-1 Receptor Antagonists Revenue by Application (2020-2031)
- 8.2.2 North America NK-1 Receptor Antagonists Sales by Application (2020-2031)
- 8.2.3 North America NK-1 Receptor Antagonists Price by Application (2020-2031)
- 8.3 North America NK-1 Receptor Antagonists Market Size by Country
- 8.3.1 North America NK-1 Receptor Antagonists Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America NK-1 Receptor Antagonists Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America NK-1 Receptor Antagonists Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
- 9 Europe
- 9.1 Europe NK-1 Receptor Antagonists Market Size by Type
- 9.1.1 Europe NK-1 Receptor Antagonists Revenue by Type (2020-2031)
- 9.1.2 Europe NK-1 Receptor Antagonists Sales by Type (2020-2031)
- 9.1.3 Europe NK-1 Receptor Antagonists Price by Type (2020-2031)
- 9.2 Europe NK-1 Receptor Antagonists Market Size by Application
- 9.2.1 Europe NK-1 Receptor Antagonists Revenue by Application (2020-2031)
- 9.2.2 Europe NK-1 Receptor Antagonists Sales by Application (2020-2031)
- 9.2.3 Europe NK-1 Receptor Antagonists Price by Application (2020-2031)
- 9.3 Europe NK-1 Receptor Antagonists Market Size by Country
- 9.3.1 Europe NK-1 Receptor Antagonists Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe NK-1 Receptor Antagonists Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe NK-1 Receptor Antagonists Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
- 10 China
- 10.1 China NK-1 Receptor Antagonists Market Size by Type
- 10.1.1 China NK-1 Receptor Antagonists Revenue by Type (2020-2031)
- 10.1.2 China NK-1 Receptor Antagonists Sales by Type (2020-2031)
- 10.1.3 China NK-1 Receptor Antagonists Price by Type (2020-2031)
- 10.2 China NK-1 Receptor Antagonists Market Size by Application
- 10.2.1 China NK-1 Receptor Antagonists Revenue by Application (2020-2031)
- 10.2.2 China NK-1 Receptor Antagonists Sales by Application (2020-2031)
- 10.2.3 China NK-1 Receptor Antagonists Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia NK-1 Receptor Antagonists Market Size by Type
- 11.1.1 Asia NK-1 Receptor Antagonists Revenue by Type (2020-2031)
- 11.1.2 Asia NK-1 Receptor Antagonists Sales by Type (2020-2031)
- 11.1.3 Asia NK-1 Receptor Antagonists Price by Type (2020-2031)
- 11.2 Asia NK-1 Receptor Antagonists Market Size by Application
- 11.2.1 Asia NK-1 Receptor Antagonists Revenue by Application (2020-2031)
- 11.2.2 Asia NK-1 Receptor Antagonists Sales by Application (2020-2031)
- 11.2.3 Asia NK-1 Receptor Antagonists Price by Application (2020-2031)
- 11.3 Asia NK-1 Receptor Antagonists Market Size by Country
- 11.3.1 Asia NK-1 Receptor Antagonists Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia NK-1 Receptor Antagonists Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia NK-1 Receptor Antagonists Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA NK-1 Receptor Antagonists Market Size by Type
- 12.1.1 SAMEA NK-1 Receptor Antagonists Revenue by Type (2020-2031)
- 12.1.2 SAMEA NK-1 Receptor Antagonists Sales by Type (2020-2031)
- 12.1.3 SAMEA NK-1 Receptor Antagonists Price by Type (2020-2031)
- 12.2 SAMEA NK-1 Receptor Antagonists Market Size by Application
- 12.2.1 SAMEA NK-1 Receptor Antagonists Revenue by Application (2020-2031)
- 12.2.2 SAMEA NK-1 Receptor Antagonists Sales by Application (2020-2031)
- 12.2.3 SAMEA NK-1 Receptor Antagonists Price by Application (2020-2031)
- 12.3 SAMEA NK-1 Receptor Antagonists Market Size by Country
- 12.3.1 SAMEA NK-1 Receptor Antagonists Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA NK-1 Receptor Antagonists Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA NK-1 Receptor Antagonists Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 NK-1 Receptor Antagonists Value Chain Analysis
- 13.1.1 NK-1 Receptor Antagonists Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 NK-1 Receptor Antagonists Production Mode & Process
- 13.2 NK-1 Receptor Antagonists Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 NK-1 Receptor Antagonists Distributors
- 13.2.3 NK-1 Receptor Antagonists Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.